Successful rechallenge with avelumab in Merkel cell carcinoma

Eur J Cancer. 2021 Aug:153:96-97. doi: 10.1016/j.ejca.2021.05.024. Epub 2021 Jun 18.

Authors

Mathilde Amiot¹, Florence Brunet Possenti², Céleste Lebbé³, Barouyr Baroudjian³

Affiliations

¹ Department of Dermatology, AP-HP Bichat Hospital, Paris, France. Electronic address: [email protected].
² Department of Dermatology, AP-HP Bichat Hospital, Paris, France.
³ Department of Dermatology, AP-HP Saint Louis Hospital, Paris, France.

PMID: 34153719
DOI: 10.1016/j.ejca.2021.05.024

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Merkel Cell / drug therapy*
Carcinoma, Merkel Cell / pathology
Humans
Male

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
avelumab